Liraglutide (T2DM)

Using liraglutide in people with obesity and prediabetes is a valuable strategy for weight loss, but improvements are greater with caloric restriction alone, suggest study results.

The addition of liraglutide rather than extra oral antidiabetic drugs may offer more sustained glycemic control for people with type 2 diabetes who have inadequate control with metformin, suggest findings of the international LIRA-PRIME study.

Findings from a phase 3 randomized crossover trial suggest that 7 weeks of treatment with liraglutide may improve forced vital capacity among people with type 2 diabetes and impaired lung function.

Treatment with the GLP-1 receptor agonist liraglutide is associated with a reduction in cardiac adipose tissue volume among people with type 2 diabetes, suggests a secondary analysis of data from the LiraFlame trial.

A post-hoc analysis of SUSTAIN 10 indicates that people with type 2 diabetes stand to gain from GLP-1 receptor agonist use even if they are already using an SGLT2 inhibitor.

Findings from the GRADE study, a head-to-head comparison of four commonly used diabetes drugs given together with metformin, suggest that liraglutide and insulin may result in better glycemic control than glimepiride and sitagliptin among people with type 2 diabetes.

Phase 2 study results suggest that add-on treatment with an anti-IL-21 antibody plus liraglutide could preserve endogenous insulin secretion in people with recent-onset type 1 diabetes.

People with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists have a lower risk for serious renal adverse events than those given dipeptidyl peptidase-4 inhibitors, indicate results from a Scandinavian real-world study.